There were associations for GLP-1 RA treatment vs placebo with improvements in restrained eating and emotional eating behavior and in mental health-related QOL. HealthDay News — For patients ...

Proportion of adult managed care organizations with availability varied from 24 to 100 percent for SGLT2 inhibitors, 0 to 99 percent for GLP-1 receptor agonists. (HealthDay News) — Many Medicaid ...

analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), further demonstrating its potential as a best-in-class obesity drug. In the 28-day ...

The result is "consistent with prior studies of injectable semaglutide and other GLP-1 receptor agonist," but a positive result is still a big deal, said principal investigator Darren K.

Orally administered PL8177 is designed to target melanocortin-1 receptors on the surface of cells lining the colon. In a Phase 1 clinical trial, the oral version of PL8177 was shown to effectively ...

Clinical Remission: Achieved in 33% of PL8177-treated patients versus 0% on placebo after eight weeks of treatment. Clinical Response (statistically significant): Demonstrated in 78% of PL8177 ...

Glucagon-like peptide-1 (GLP-1) receptor agonists, a class of medications widely used in the treatment of type 2 diabetes (T2D), have shown significant effectiveness in both lowering blood sugar ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients. The finding contrasts with positive results from previous phase II ...

Kidney stones are among the possible risks of GLP-1 use that were not previously known. Glucagon-like peptide 1 receptor agonists (GLP-1RAs) may have a wider range of benefits and risks than what ...

Study: Suicide and suicide attempt in users of GLP-1 receptor agonists: a nationwide case-time-control study. Image Credit: KK Stock/Shutterstock.com In a recent study published in the ...

With evidence from 85,373 participants across 11 trials, GLP-1 receptor agonists significantly reduced kidney failure risk and cardiovascular events, showing consistent benefits across diabetes ...